Product Description
a potent oral small molecule galectin-3 inhibitor
Mechanisms of Action: GAL3 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Galecto Biotech
Company Location: BOSTON MA 02109
Company CEO: Hans T. Schambye
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, France, Netherlands, Poland, Spain, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 2: Head and Neck Cancer|Liver Cirrhosis|Melanoma|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05913388 | P2 |
Recruiting |
Head and Neck Cancer|Melanoma|Squamous Cell Carcinoma |
2028-02-01 |
|
| GALLANT-1 | P2 |
Unknown Status |
Non-Small-Cell Lung Cancer |
2025-08-01 |
|
| GALLANT-1 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2025-02-16 |
|
| GALLANT-1 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2024-05-30 |
57% |